Eli Lilly and Company $LLY Shares Sold by Sumitomo Life Insurance Co.

Sumitomo Life Insurance Co. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 8.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,459 shares of the company’s stock after selling 2,621 shares during the quarter. Eli Lilly and Company accounts for 0.7% of Sumitomo Life Insurance Co.’s portfolio, making the stock its 26th biggest holding. Sumitomo Life Insurance Co.’s holdings in Eli Lilly and Company were worth $21,714,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Exencial Wealth Advisors LLC grew its position in Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after buying an additional 11,396 shares during the period. Rede Wealth LLC purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $487,000. Central Pacific Bank Trust Division grew its holdings in shares of Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after acquiring an additional 1,843 shares during the period. Cidel Asset Management Inc. grew its holdings in shares of Eli Lilly and Company by 26.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after acquiring an additional 5,591 shares during the period. Finally, Oak Family Advisors LLC purchased a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $1,979,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s oral obesity candidate completed an early trial stage, sharpening investor focus on a potential oral GLP‑1/GIP pathway competitor to injectables — a major long‑term revenue lever if translated to late‑stage success. TipRanks: Oral obesity trial completion
• Positive Sentiment: Positive Phase 3 VIVID‑2 open‑label extension results for Omvoh (mirikizumab) bolster Lilly’s non‑GLP‑1 pipeline (Crohn’s/UC), reducing single‑product concentration risk and adding near‑term commercial optionality. Yahoo Finance: VIVID‑2 results
• Positive Sentiment: Analysts have largely stayed constructive: Truist reaffirmed a buy rating and Goldman/Goldman‑coverage notes (and price targets) remain supportive, which can limit downside from headline volatility. MarketScreener: Truist reaffirms buy
• Neutral Sentiment: Bank of America and other firms argue Novo’s announced list‑price cuts are unlikely to meaningfully dent U.S. GLP‑1 volumes for rivals in the near term, suggesting the sector pricing move may be more tactical than market‑eroding. That view helps explain why some investors see the price cut as contained risk rather than an existential threat to Lilly’s sales. Yahoo Finance: BofA sees limited impact
• Neutral Sentiment: Macro/sector coverage pieces and long‑term growth analyses highlight that Lilly’s GLP‑1 blockbusters (Mounjaro/Zepbound) drove a majority of recent revenue growth, keeping the long‑term story intact even as short‑term headlines create choppiness. Zacks: GLP‑1 revenue drivers
• Negative Sentiment: Novo Nordisk announced plans to cut U.S. list prices for Wegovy/Ozempic by up to ~50% starting in 2027 — a direct sector shock that triggered investor worry about pricing pressure, broader margin implications and potential share‑loss dynamics across GLP‑1 makers. That news is the primary reason for today’s downward pressure. Yahoo Finance: Novo halves US price
• Negative Sentiment: Several outlets flagged that investors reacted nervously — and some short‑term selloffs followed — after the Novo pricing announcement and prior trial headlines; that volatility can amplify intraday declines despite Lilly’s strong fundamentals. Fool: Why LLY slumped

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,030.30 on Thursday. The firm has a 50 day simple moving average of $1,054.25 and a 200-day simple moving average of $924.46. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The firm has a market cap of $971.95 billion, a PE ratio of 44.89, a P/E/G ratio of 1.21 and a beta of 0.39. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company’s revenue was up 42.6% compared to the same quarter last year. During the same quarter last year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 30.15%.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. Wolfe Research boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. BMO Capital Markets restated an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,229.33.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.